manipalhospitals
LIFE'S ON

# DEPARTMENT OF MEDICAL GENETICS
# NEXT GENERATION SEQUENCING TEST REPORT [AMENDED]

| | | | |
|---|---|---|---|
| **Hospital No.** | MH001145657 | **Referral Hospital** | Manipal Hospital MNSH |
| **Patient Name** | Ms Radhika Subramani | **Sample Collection Date** | 11-08-2026 |
| **Age / Gender** | 22 years / Female | **Test Initiation Date** | 13-08-2026 |
| **Test Requested** | Whole Genome Sequencing | **Report Date** | 17-10-2026 |
| **Referred by** | Dr Deepesh V | **Specimen** | Peripheral blood |

## CLINICAL DIAGNOSIS / FEATURES / HISTORY

Ms Radhika Subramani is presented with childhood-onset steroid-resistant nephrotic syndrome diagnosed at 10 years of age, persistent proteinuria despite immunosuppressive therapy, progressive renal dysfunction and chronic kidney disease. Previous renal biopsy demonstrated mesangial proliferative glomerulonephritis. Her sample has been evaluated to investigate an underlying genetic etiology of hereditary nephrotic syndrome and progressive kidney disease. Her WES + mitochondrial report – normal. She has been evaluated for the gene variants related to the phenotype.

## RESULT

**No disease-causing pathogenic or likely pathogenic variant or No significant single nucleotide variation (SNV) or copy number variation (CNV) related to the phenotypes was detected in this sample**

## RECOMMENDATIONS

- Genetic Counseling

## METHODOLOGY

Sequencing of the protein coding regions approximately 3 GB of the Human Genome build of hg/GRCh38 and complete mitochondrial genome sequencing was performed using MGI next generation sequencing (NGS) systems at a mean depth of 30X with percentage of bases covered at 20X depth >90% in the target region and the depth for mitochondrial genome at 1000-2000X. In some cases, due to the complexity of the sequence, not all variants in the flanking regions are able to be analyzed. A base is considered to have sufficient coverage at 20X and an exon is considered fully covered if all coding bases plus three nucleotides of flanking sequence on either side are covered at 20X or more. GATK best practice framework was followed for variant identification. Duplicate reads identification and removal, Base quality recalibration and re-alignment of reads based on indels were done using DRAGEN BIO IT platform (2). Quality checks (QC) will be performed on all VCF files to exclude variants where sequencing is of poor quality. Additional QC metrics includes total homozygous and heterozygous calls (SNVs and indels), proportion of variant calls that were common, number of variants falling into different annotated consequence categories, number of extreme heterozygotes (alternate allele proportion 0.8). Variant annotations will be done using published databases like OMIM, GWAS, GNOMAD, 1000Genome etc (3-6). Non-synonymous variants effect is calculated using multiple algorithms such as PolyPhen-2, SIFT, MutationTaster2, Mutation Assessor and LRT. Non-synonymous and splice site variants will be used for clinical interpretation. Silent variations that do not result in any change in amino acid in the coding region are not reported. Geneyx (version 6.3) was used for variant annotation, analysis and reporting (7).

## LIMITATIONS AND DISCLAIMER

Any preparation and processing of a sample from patient material provided to the department of medical genetics for the requested genetic testing is performed on the highest and most current scientific and analytical standards. Currently available data indicates that technical error rate for analysis involving DNA tests is anywhere between 1-3%. In order to minimize this inherent limitation of targeted gene panel sequencing, a high coverage depth (>100X) is ensured and >90% of all amplicons are covered at least by 20X. Intronic variants are not assessed using this method. Test results are always interpreted in the context of clinical findings, family history and other laboratory data. Rare polymorphisms may lead to false negative or positive results. This does not imply that reported variants can always explain all symptoms of the patient. Copy number variations or large deletion/duplications may not be detected by NGS. Incidental or secondary findings (if any) that meet the ACMG guidelines can also be given upon request. Additionally, it is possible that a particular genetic abnormality may not be recognized as the underlying cause of the genetic disorder due to incomplete scientific knowledge about the impact of variants on those genes. Not all variants detected may be listed in the report. Inclusion of variants is dependent upon provided clinical information, its significance and currently available literature. Incidental or secondary findings (if any) that meet the ACMG guidelines can also be given upon request. The classification of variants of unknown significance can change over time.

Mitesh

**DR.MITESH SHETTY**
HOD & Consultant Medical Geneticist

## REFERENCES:


1. Richards, S., and Voelkerding, K., 2015. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in medicine*, *17*(5), p.405.
2. Freed D. et al., The Sentieon Genomics Tools-A fast and accurate solution to variant calling from next-generation sequence data. BioRxiv:115717, 2017.
3. https://cloud.google.com/life-sciences/docs/tutorials/deepvariant
4. Landrum et ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res., 44(D1):D862-8, 2015.
5. Welter D. et al., The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res., 42:D1001-1006.
6. 1000 Genomes Project Consortium et al., A global reference for human genetic variation. Nature, 526(7571): 68-74, 2015.
7. https://analysis.geneyx.com/
8. Meyer, L.R., et al., The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res, 2013. 41(D1): p. D64-9.
9. McKenna, A., et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res, 2010. 20(9): 1297-303.
10. http://www.mitomap.org/MITOMAP
11. https://www.ncbi.nlm.nih.gov/clinvar/docs/acmg/
12. Austin-Tse, C.A., Jobanputra, V., Perry, D.L. et al. Best practices for the interpretation and reporting of clinical whole genome sequencing. npj Genom. Med. 7, 27 (2022). https://doi.org/10.1038/s41525-022-00295-z
13. W. -T. Yang *et al*., "Evaluation of using WGS/WES to characterize ACMG actionable genes in genetic testing reports," *2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)*, Houston, TX, USA, 2021, pp. 1691-1693, doi: 10.1109/BIBM52615.2021.9669752.


******** End of the report *********